Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Cardiac Inflammation after COVID-19 mRNA Vaccines: A Global Pharmacovigilance Analysis

View ORCID ProfileLaurent Chouchana, View ORCID ProfileAlice Blet, View ORCID ProfileMohammad Al-Khalaf, Tahir S. Kafil, Girish Nair, James Robblee, View ORCID ProfileMilou-Daniel Drici, View ORCID ProfileMarie-Blanche Valnet-Rabier, Joëlle Micallef, View ORCID ProfileFrancesco Salvo, View ORCID ProfileJean-Marc Treluyer, Peter P. Liu
doi: https://doi.org/10.1101/2021.08.12.21261955
Laurent Chouchana
1Regional Center of Pharmacovigilance, Department of Pharmacology, Cochin Hospital, AP-HP.Centre – Université de Paris, Paris, France
PharmD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Laurent Chouchana
Alice Blet
2University of Ottawa Heart Institute, Departments of Medicine and Cellular & Molecular Medicine (P.P.L., M.A.K), University of Ottawa, Ontario, Canada
3Department of Anesthesiology, Critical Care and Burn Center, Lariboisière - Saint-Louis Hospitals, DMU Parabol, AP–HP Nord, University of Paris, France
4Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions (MASCOT), University of Paris, France
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alice Blet
Mohammad Al-Khalaf
2University of Ottawa Heart Institute, Departments of Medicine and Cellular & Molecular Medicine (P.P.L., M.A.K), University of Ottawa, Ontario, Canada
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mohammad Al-Khalaf
Tahir S. Kafil
2University of Ottawa Heart Institute, Departments of Medicine and Cellular & Molecular Medicine (P.P.L., M.A.K), University of Ottawa, Ontario, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Girish Nair
2University of Ottawa Heart Institute, Departments of Medicine and Cellular & Molecular Medicine (P.P.L., M.A.K), University of Ottawa, Ontario, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Robblee
2University of Ottawa Heart Institute, Departments of Medicine and Cellular & Molecular Medicine (P.P.L., M.A.K), University of Ottawa, Ontario, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Milou-Daniel Drici
5Regional Center of Pharmacovigilance, Department of Pharmacology, Nice University Hospital, Nice, France
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Milou-Daniel Drici
Marie-Blanche Valnet-Rabier
6Regional Center of Pharmacovigilance, Department of Pharmacology, Besançon University Hospital, Besançon, France
PharmD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marie-Blanche Valnet-Rabier
Joëlle Micallef
7UMR 1106, Institute of Neurosciences System, Aix-Marseille University, Inserm, Marseille, France. Regional center of Pharmacovigilance, Department of Clinical Pharmacology and Pharmacovigilance, University Hospitals of Marseille, Marseille, France
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesco Salvo
8Univ. Bordeaux, INSERM, BPH, U1219, F-33000 Bordeaux, France
9CHU de Bordeaux, Pôle de Santé Publique, Service de Pharmacologie médicale, Centre Régional de Pharmacovigilance, Bordeaux
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Francesco Salvo
Jean-Marc Treluyer
1Regional Center of Pharmacovigilance, Department of Pharmacology, Cochin Hospital, AP-HP.Centre – Université de Paris, Paris, France
10University of Paris, Paris, France
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jean-Marc Treluyer
Peter P. Liu
2University of Ottawa Heart Institute, Departments of Medicine and Cellular & Molecular Medicine (P.P.L., M.A.K), University of Ottawa, Ontario, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: peter.liu@utoronto.ca pliu@ottawaheart.ca
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background To counter the COVID-19 pandemic, mRNA vaccines, namely tozinameran and elasomeran, have been authorized in several countries. These next generation vaccines have shown high efficacy against COVID-19 and demonstrated a favorable safety profile. As widespread vaccinations efforts are taking place, incidents of myocarditis and pericarditis cases following vaccination have been reported. This safety signal has been recently confirmed by the European Medicine Agency and the U.S. Food and Drug Administration.

This study aimed to investigate and analyze this safety signal using a dual pharmacovigilance database analysis.

Methods This is as an observational study of reports of inflammatory heart reactions associated with mRNA COVID-19 vaccines reported in the World Health Organization’s global individual case safety report database (up to June 30th 2021), and in the U.S. Vaccine Adverse Event Reporting System (VAERS, up to May 21st 2021). Cases were described, and disproportionality analyses using reporting odds-ratios (ROR) and their 95% confidence interval (95%CI) were performed to assess relative risk of reporting according to patient sex and age.

Results At a global scale, the inflammatory heart reactions most frequently reported were myocarditis (1241, 55%) and pericarditis (851, 37%), the majority requiring hospitalization (n=796 (64%)). Overall, patients were young (median age 33 [21-54] years). The main age group was 18-29 years old (704, 31%), and mostly males (1555, 68%). Pericarditis onset was delayed compared to myocarditis with a median time to onset of 8 [3-21] vs. 3 [2-6] days, respectively (p=0.001). Regarding myocarditis, an important disproportionate reporting in males (ROR, 9.4 [8.3-10.6]) as well as in adolescents (ROR, 22.3 [19.2-25.9]) and 18-29 years old (ROR, 6.6 [5.9-7.5]) compared to older patients were observed.

Conclusions The inflammatory heart reactions, namely myocarditis and pericarditis, have been reported world-wide shortly following COVID-19 mRNA vaccination. An important disproportionate reporting among adolescents and young adults, particularly in males, was observed especially for myocarditis. Guidelines must take this specific risk into account and to optimize vaccination protocols according to sex and age. While the substantial benefits of COVID-19 vaccination still prevail over risks, clinicians and the public should be aware of these reactions and seek appropriate medical attention.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work is supported in part by research grants from the Canadian Institutes of Health Research, Heart & Stroke Foundation of Canada, Genome Canada, and University of Ottawa of Heart Institute.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study has obtained ethics approval from the Cochin university Hospital institutional review board (number AAA-2021-08039) in conformity with the French laws and regulations. All of the data used for analysis were de-identified, and only aggregate data are reported.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* LC andAB share first position authorship.

  • ↵¶ Laurent Chouchana, Milou-Daniel Drici, Marie-Blanche Valnet-Rabier, Joëlle Micallef, Francesco Salvo and Jean-Marc Treluyer are members of the French Pharmacovigilance Network.

Data Availability

data available upon reasonable request

  • ABBREVIATION LIST

    CDC
    Centers for Disease Control and Prevention
    95%CI
    Confidence Interval 95%
    COVID-19
    coronavirus disease
    FDA
    U.S. Food and Drug Administration
    IQR
    interquartile range
    MedDRA
    Medical Dictionary for Regulatory Activities
    mRNA
    messenger RNA
    OR
    Odds Ratio
    ROR
    Reporting Odds Ratio
    VAERS
    Vaccine Adverse Event Reporting System
    WHO
    World Health Organization
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
    Back to top
    PreviousNext
    Posted August 18, 2021.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Cardiac Inflammation after COVID-19 mRNA Vaccines: A Global Pharmacovigilance Analysis
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Cardiac Inflammation after COVID-19 mRNA Vaccines: A Global Pharmacovigilance Analysis
    Laurent Chouchana, Alice Blet, Mohammad Al-Khalaf, Tahir S. Kafil, Girish Nair, James Robblee, Milou-Daniel Drici, Marie-Blanche Valnet-Rabier, Joëlle Micallef, Francesco Salvo, Jean-Marc Treluyer, Peter P. Liu
    medRxiv 2021.08.12.21261955; doi: https://doi.org/10.1101/2021.08.12.21261955
    Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    Cardiac Inflammation after COVID-19 mRNA Vaccines: A Global Pharmacovigilance Analysis
    Laurent Chouchana, Alice Blet, Mohammad Al-Khalaf, Tahir S. Kafil, Girish Nair, James Robblee, Milou-Daniel Drici, Marie-Blanche Valnet-Rabier, Joëlle Micallef, Francesco Salvo, Jean-Marc Treluyer, Peter P. Liu
    medRxiv 2021.08.12.21261955; doi: https://doi.org/10.1101/2021.08.12.21261955

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Pharmacology and Therapeutics
    Subject Areas
    All Articles
    • Addiction Medicine (271)
    • Allergy and Immunology (553)
    • Anesthesia (135)
    • Cardiovascular Medicine (1761)
    • Dentistry and Oral Medicine (238)
    • Dermatology (173)
    • Emergency Medicine (312)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (660)
    • Epidemiology (10803)
    • Forensic Medicine (8)
    • Gastroenterology (592)
    • Genetic and Genomic Medicine (2952)
    • Geriatric Medicine (287)
    • Health Economics (534)
    • Health Informatics (1930)
    • Health Policy (836)
    • Health Systems and Quality Improvement (745)
    • Hematology (293)
    • HIV/AIDS (631)
    • Infectious Diseases (except HIV/AIDS) (12519)
    • Intensive Care and Critical Care Medicine (693)
    • Medical Education (299)
    • Medical Ethics (86)
    • Nephrology (324)
    • Neurology (2801)
    • Nursing (151)
    • Nutrition (433)
    • Obstetrics and Gynecology (559)
    • Occupational and Environmental Health (597)
    • Oncology (1469)
    • Ophthalmology (444)
    • Orthopedics (172)
    • Otolaryngology (257)
    • Pain Medicine (190)
    • Palliative Medicine (56)
    • Pathology (381)
    • Pediatrics (867)
    • Pharmacology and Therapeutics (366)
    • Primary Care Research (337)
    • Psychiatry and Clinical Psychology (2641)
    • Public and Global Health (5374)
    • Radiology and Imaging (1013)
    • Rehabilitation Medicine and Physical Therapy (596)
    • Respiratory Medicine (726)
    • Rheumatology (330)
    • Sexual and Reproductive Health (289)
    • Sports Medicine (279)
    • Surgery (327)
    • Toxicology (47)
    • Transplantation (150)
    • Urology (125)